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Mycotoxins are toxic, secondary metabolites produced by fungi. They occur in a wide variety 
of food and feed commodities, and are of major public health concern because they are the 
most hazardous of all food and feed contaminants in terms of chronic toxicity. In the past 
decades, it has become clear that in mycotoxin-contaminated commodities, many structurally 
related compounds generated by plant metabolism, fungi or food processing coexist with their 
free mycotoxins, defined as modified mycotoxins. These modified xenobiotics might 
endanger animal and human health as they are possibly hydrolysed into their free toxins in the 
digestive tract of mammals, and may consequently contribute to an unexpected high toxicity. 
As modified toxins represent an emerging issue, it is not a surprise that for most toxicological 
tests data are scarce to non-existent. Therefore, there is a need to elucidate the disposition and 
kinetics of both free and modified mycotoxins in mammals to correctly interpret occurrence 
data and biomonitoring results. This review emphasizes the current knowledge on the 
metabolism of modified mycotoxins using in vitro and in vivo models. 
 
 




Mycotoxins are toxic, low-molecular-weight, secondary metabolites produced by fungi. They 
function as insecticides, play a role in fighting against plant defence to the fungus, and they 
assist the fungus in some way to compete for their ecological niche in nature (Richard et al. 
2007). Mycotoxins are of a major public health concern because they are the most hazardous 
of all food and feed contaminants in terms of chronic toxicity (Kuiper-Goodman 1998). Some 
mycotoxins are harmful to other micro-organisms such as other fungi or even bacteria, like 
the antibiotic penicillin, produced by Penicillium chrysogenum (Fleming 1929); others are 
potent carcinogens like aflatoxins. The most important fungal genera producing mycotoxins 
that are found in food products are Aspergillus, Fusarium, Alternaria, Claviceps and 
Penicillium. 
In the past decades, it has become clear that in mycotoxin-contaminated commodities, many 
structurally related compounds generated by plant metabolism, fungi or food processing 
coexist with their free mycotoxins. In the mid 80ies the topic of masked mycotoxins received 
attention because in some cases of mycotoxicosis, clinical observations in animals did not 
correlate with the low mycotoxin content determined in the corresponding feed (Gareis et al. 
1990). The unexpected high toxicity was attributed to undetected conjugated forms of 
mycotoxins, that possibly were hydrolysed into the free toxins in the digestive tract of 
animals. Thus, knowledge on the occurrence of these mycotoxin forms is imperative to 
unequivocally determine the mycotoxicological load of food or feed products.  
The term masked mycotoxins was firstly introduced by Gareis et al. (1990) revealing the 
cleavage of zearalenone-14-glucoside (ZEN-14G) during digestion in swine (Gareis et al. 
1990). The primary definition expressed masked mycotoxins as molecules, not detectable by 
standard routine analysis. Berthiller et al. (2013), however, suggested to use the term of 
masked mycotoxins, solely for the description of plant derivatives of mycotoxins (Berthiller et 
al. 2012). Continuing this line of reasoning, Rychlik et al. (2014) highlighted the necessity to 
systematize the nomenclature of mycotoxin conjugates, in order to avoid further 
misunderstanding (Rychlik et al. 2014). The term modified mycotoxins was introduced to 
describe all types of mycotoxins modifications on four levels. The first level distinguishes 
free mycotoxins from those being matrix-associated, chemically or biologically modified. 
Free mycotoxins are designated compounds, produced as secondary metabolites of microfungi 
causing disease and death in humans and other species (e.g. aflatoxins, patulin or zearalenone 
(ZEN)). The mentioned definition of modified mycotoxins will allow systematizing 
nomenclature of mycotoxin-conjugates, and helps to uniform this topic in future. 
The presence of modified mycotoxins was revealed in cereal-based food and feed for 
trichothecenes, myco-estrogens and fumonisins. More specifically deoxynivalenol-3-
glucoside (DON-3G), zearalenone-14-glucoside (ZEN-14G), zearalenone-14-sulfate (ZEN-
14S), α-zearalenol-14-glucoside (α-ZEL-14G), β-zearalenol-14-glucoside (β-ZEL-14G), T-2-
toxin-3-glucoside (T-2-3G), HT-2-toxin-3-glucoside (HT-2-3G), diacetoxyscirpenol-3-
glucoside (DAS-3G), nivalenol-3-glucoside (NIV-3G), mono-acetoxyscirpenol-3-glucoside 
(MAS-3G), neosolaniol-3-glucoside (NEO-3G) and fumonisins-esters (Berthiller et al. 2005; 
Berthiller et al. 2012; Dall'Asta et al. 2009a; Dall'Asta et al. 2009b; De Boevre et al. 2012; 
De Boevre et al. 2014; Nakagawa et al. 2013a; Nakagawa et al. 2011; Nakagawa et al. 
2013b) were detected and confirmed. 
It has become clear that modified mycotoxins could represent a potential additional risk for 
both animals and humans. However, despite the enormous progress, many research challenges 
remain since essential information is still lacking, and more studies are urgently needed to 
unravel the true modified mycotoxin problemacy. Nevertheless, most concerns are related to 
the potential health effects of conjugated forms of mycotoxins. Either direct toxic effects of 
the conjugated forms, or indirect toxicity via hydrolysis to their free forms can be attributed to 
modified mycotoxins. Only few reports indicated the possible toxic relevance of conjugated 
forms. In the near future, full-scale metabolism studies could reveal relevant toxicity data by 
incorporating modified mycotoxins in vivo. 
 
IN VITRO STUDIES 
To determine the impact of modified mycotoxins on human health, the scientific community 
requested to investigate the complete metabolic profile of these forms (European Food Safety 
Authority 2014). Up to now, data regarding the in vivo toxicological relevance of modified 
mycotoxins were lacking. As modified toxins represent an emerging issue, it is not a surprise 
that for most toxicological tests no data are available, such as genotoxicity, short-term and 
long-term toxicity including carcinogenicity, reproduction and developmental studies. As 
conjugation is known to be a detoxification process in planta, it seems likely that conjugated 
mycotoxins exhibit a lower acute toxicity compared to their free compounds. The accessibility 
and the high degree of complexity of in vivo trials limit the acquisition of information on 
health effects of specific processes. For this reason, in vitro batch incubations have been 
executed to circumvent these complexities. In vitro studies were designed to mimick natural 
conditions during digestion, and to check the fate of modified mycotoxins during contact with 
stomach juices and interaction with human colonic microbiota. Recently, Berthiller et al. 
demonstrated the possible toxicological relevance of DON-3G by demonstrating that several 
lactic acid bacteria hydrolyse DON-3G during digestion in vitro (Berthiller et al. 2011). 
Acidic conditions, hydrolytic enzymes and intestinal bacteria, respectively, mimicking 
different stages of digestion, were included. DON-3G was found resistant to 0.2 M HCl for at 
least 24 h at 37 °C (pH 1.7), suggesting that the conjugated form will not be hydrolysed in the 
stomach of mammals. While human cytosolic β-glucosidase also had no effect, forty-seven 
different bacterial strains, isolated from the gut, were examined towards their ability to 
hydrolyse DON-3G. Fungal cellulase and cellobiase, and more specifically lactic acid 
bacteria, such as Enterococcus durans, Enterococcus mundtii or Lactobacillus plantarum, 
could cleave a significant portion of DON-3G. 
Furthermore, De Nijs et al. (2012) investigated an in vitro static digestive simulation model 
mimicking the upper gastro-intestinal tract (saliva and stomach) and the lower gastro-
intestinal tract (small intestine) (De Nijs et al. 2012). The transformation of DON-3G in the 
small intestine was assessed by adoption of Caco-2 cells in a Transwell
®
 system. The authors 
likewise reported that deoxynivalenol (DON) was not released from DON-3G in the 
mammals’ stomach and was resistant to human cytosolic β-glucosidase. There was no 
evidence of the release of DON from DON-3G spiked at a level of 2,778 μg DON-3G/kg food 
during the complete simulation protocol. 
Besides DON, ZEN and its derivatives were also investigated. Recently, Dall'Erta et al. 
(2013) demonstrated that these modified forms were effectively deconjugated by human 
colonic microbiota, releasing their toxic aglucones and generating unidentified catabolites 
using an in vitro batch incubation experiment (Dall'Erta et al. 2013). The tremendous amount 
of different bacterial strains and associated enzymes in the human colon makes the 
gastrointestinal tract a remarkable bioreactor, able to chemically transform most of 
compounds ingested by humans. An in vitro digestion assay was performed for DON-3G, 
ZEN-14G and ZEN-14S by the use of four synthetic juices, namely saliva, gastric juice, 
duodenal juice and bile juice. After incubation in these phases the modified mycotoxins were 
fully recovered with amounts of 99.5%, 97.3% and 98.6%, respectively. Concurrently, an in 
vitro fecal fermentation assay was executed at time frames of 30 minutes and 24h. In contrast, 
when an in vitro fecal fermentation assay was conducted, the modified mycotoxin forms 
ZEN-14G and ZEN-14S were completely cleaved after 24h. Remarkably, ZEN, however, was 
only partially recovered in the fecal slurry which implied further degradation of ZEN in this 
specific section of the digestive tract and the presence of unknown catabolites of ZEN. 
Regarding DON-3G, this conjugate was also not deglucosylated after 30 min. Complete 
degradation (90% DON) was observed in the fecal slurry after 24h. Discrepancies in the 
anatomy and gut microbiota were proven in this study as only traces of DOM-1 were found in 
humans. 
Modified fumonisins were evaluated using the same static digestion model (Dall'Asta et al. 
2010; Falavigna et al. 2012). The various stages were reproduced with the exception of gut 
microbiota fermentation, and permeation of transport across the intestinal epithelium. The 
studies proved that upon digestion, hidden fumonisins (non-covalently, bound molecules) 
released their free forms, whereas bound fumonisins (covalently, bound particles) were rather 
stable during in vitro digestion (Falavigna et al. 2012). On the other hand, Dall’asta et al. 
(2010) reported an increased amount (30% to 50%) of total detectable fumonisins upon 
digestion of the food matrix (Dall'Asta et al. 2010). These data confirmed that gastrointestinal 
enzymes are able to destroy the matrix-fumonisin interactions, thus releasing the hidden 
forms. The occurrence of both hidden and bound fumonisins can be evaluated by indirect 
determination after alkaline hydrolysis, as these forms are completely cleaved to hydrolysed 
fumonisins. A tabulated summary of key findings from these in vitro studies with modified 
mycotoxins are pointed out in Table 1. 
 
Table 1: tabulated summary of key findings from in vitro and in vivo studies with modified mycotoxins 
(modified) mycotoxin methodology key finding reference 
IN VITRO METABOLISM 
Deoxynivalenol-3-glucoside Static digestive simulation 1% to 62% conversion rate to DON with fungal cellulase, cellobiase and lactic acid bacteria (Berthiller et al. 2011) 
Deoxynivalenol-3-glucoside Static digestive simulation 0% conversion rate to DON with salivary and gastric phase, and human cytosolic β-glucosidase (De Nijs et al. 2012) 
Deoxynivalenol-3-glucoside Static batch incubation 0.5% conversion rate to DON with salivary, gastric, duodenal phase (i.e. 99.5% recovery of DON-3G) (Dall'Erta et al. 2013) 
 Fecal fermentation 90% conversion rate to DON with human colonic microbiota (Dall'Erta et al. 2013) 
Zearalenone-14-glucoside Static batch incubation 2.7% conversion rate to ZEN with salivary, gastric, duodenal phase (i.e. 97.3% recovery of ZEN-14G) (Dall'Erta et al. 2013) 
 Fecal fermentation 40% conversion rate to ZEN with human colonic microbiota + 60% other ZEN-catabolites (Dall'Erta et al. 2013) 
Zearalenone-14-sulphate Static batch incubation 1.4% conversion rate to ZEN with salivary, gastric, duodenal phase (i.e. 98.6% recovery of ZEN-14S) (Dall'Erta et al. 2013) 
 Fecal fermentation 40% conversion rate to ZEN with human colonic microbiota + 60% other ZEN-catabolites (Dall'Erta et al. 2013) 
Hidden fumonisins Static batch incubation 70% to 99% conversion rate to free fumonisins under digestive conditions (Dall'Asta et al. 2010) 
Bound fumonisins Static batch incubation 0% conversion rate to free fumonisins under digestive conditions (Falavigna et al. 2012) 
IN VIVO METABOLISM 
Deoxynivalenol-3-glucoside in vivo – rats 2% to 3% conversion rate to DON in the gastric phase 
Small amounts of DON-3G in the small intestine (2% to 3%) and colon (1% to 2%) 
(Versilovskis et al. 2012) 
3-and 15-acetyldeoxynivalenol in vivo – rats 11.4% (3-ADON) to 12.5% (15-ADON) conversion rate to DON in the gastric phase 
Small intestine: 0% of free 3-ADON and 15-ADON; 4.5% to 6.5% 3-ADON-glucuronide; 
0.6% 15-ADON-glucuronide; high amount DON-3-glucuronide (i.e. deacetylation and glucuronidation) 
(Versilovskis et al. 2012) 
Zearalenone-14-glucoside in vivo – rats 16% to 19% conversion rate to ZEN in the gastric phase 
Small amounts of ZEN-14G in the small intestine 
No confirmation of α-zearalenol, β-zearalenol or ZEN-glucuronides 
(Versilovskis et al. 2012) 
Deoxynivalenol-3-glucoside in vivo – rats Urine: recovery of 21% of DON-3G 
Faeces: major recovery of DON and deepoxy-deoxynivalenol, no explanation for remaining 79% DON-3G 
(Nagl et al. 2012) 
Deoxynivalenol-3-glucoside in vivo – pigs Urine: recovery of 85% DON and 40% of DON-3G 
Faeces: traces amounts of analysed mycotoxins 
(Nagl et al. 2014a) 
Hidden and bound fumonisins no data available   
 
IN VIVO STUDIES 
In vitro results allow to obtain a preliminary indication of the biotransformation and 
conversion of modified mycotoxins such as DON-3G, ZEN-14G, ZEN-14S, α-ZEL-14G, β-
ZEL-14G and fumonisins-esters. In vitro trials are firstly elaborated to reduce animal 
experiments, which benefits the 3R-principle. Another limitation of the studies are the size 
and complexity of in vivo trials, and, most importantly, the limited amount of reference 
standards available. 
To date, only few toxicokinetic and toxicodynamic investigations in mammals were 
performed, although required to further assess the risk of modified mycotoxins. The partial 
hydrolysis of modified mycotoxins during digestion in mammals will lead to an increased 
health risk. The role of the gut microbiota is becoming a key point for the investigation of 
xenobiotic bioactivity in humans and animals. To ascertain the statements regarding modified 
derivatives, a full-toxicokinetic metabolism study needs to be carried out, by the incorporation 
of mycotoxins in feed of species reliable as to extrapolation to humans, i.e. piglets. The pig 
has remarkable similarities with human beings with respect to the cardiovascular system, 
renal function, hepatic and gastrointestinal characteristics (Witkamp and Monshouwer 1998). 
So far, the effect of modified mycotoxins was investigated on rats (Nagl et al. 2012; 
Versilovskis et al. 2012) and pigs (Gareis et al. 1990; Nagl et al. 2014b). 
Recently, a study was executed on the metabolisation of glucosides of DON, acetylated DON 
(ADON) and ZEN-14G in rats (Versilovskis et al. 2012). After administration of ZEN-14G, 
ZEN was found in the stomach (16%-19%), suggesting the possibility of hydrolysis. This was 
also concluded for the acetylated DON-forms, where 11.4% (3ADON) and 12.5% (15-
ADON) of free DON was observed. However, they could not detect DON (2%-3%) in the 
stomach of rats exposed to DON-3G, confirming the in vitro results (acidic hydrolysis) of 
Berthiller et al. (2011) (Berthiller et al. 2011). Small amounts of ZEN-14G were detectable in 
the small and large intestines suggesting that they were not fully hydrolyzed. Also, 
Versilovskis et al. (2012) reported the formation of glucuronidated acetyl-DON (Versilovskis 
et al. 2012). Rats were able to directly glucuronidate ADONs without deacetylation. Neither 
de-epoxydeoxynivalenol (DOM), α-zearalenol (α-ZEL) or β-zearalenol (β-ZEL) nor their 
glucuronides could, however, be quantified. Glucuronidated 3-acetyl-deoxynivalenol (3-
ADON-Glu) accumulated in the small intestines, together with deoxynivalenol-3-glucuronide 
(DON-3Glu) in orally fed rats with 3- and 15-ADON. The large occurrence of α-ZEL 
(Videmann et al. 2012) and a sharp decrease of ZEN-14G in the small intestine suggested 
hydrolysis (Versilovskis et al. 2012), as a consequence, the total human exposure and risk 
assessment to mycotoxins might be underestimated. ZEN is converted into α-ZEL and β-ZEL, 
which are subsequently conjugated with glucuronic acid and excreted in the urine of 
mammals (JECFA 2010; Zinedine et al. 2007). It appears likely that the toxic (estrogenic) 
effects of ZEN-14G equal that of ZEN in mammals. 
Nagl et al. (2012) reported that DON-3G is partly bioavailable in rats (Nagl et al. 2012). Six 
rats received water, DON (2.0 mg/kg body weight (bw)) and the equimolar amount of DON-
3G (3.1 mg/kg bw) by gavage on day 1, 8 and 15, respectively. Urine and faeces were 
collected and analysed for DON-3G, DON, deoxynivalenol-glucuronide (DON-Glu) and 
DOM by a validated LC-MS/MS method. Whereas only 21% of the administered DON-3G 
could be recovered, the majority was recovered as DON and DOM in faeces. The authors 
concluded that digestion of DON-3G occurred in the distal part of the intestines. However no 
explanation was available for the 79% of the DON-3G which was not recovered. The authors 
concluded that DON-3G present in food and feed seems to have a significantly lower toxic 
equivalency compared to DON. However, due to the differences regarding the gastrointestinal 
anatomy and physiology and gut microbial composition and metabolic activity, the 
bioavailability and metabolisation may exhibit species dependent properties and should be 
experimentally determined (Nagl et al. 2012). Therefore, according to previous assumptions, 
DON-3G might be cleaved during digestion in pigs (Nagl et al. 2014a). Four piglets received 
water ad libitum, the modified mycotoxin DON-3G (116 mg/kg bw) and the equimolar 
amount of DON (75 mg/kg bw) by gavage on day 1, 5 and 9. Additionally, 15.5 mg DON-
3G/kg bw were intravenously administered on day 13. Urine and faeces were collected and 
analysed for DON, DON-3G, DON-3Glu, deoxynivalenol-15-glucuronide (DON-15-Glu) and 
DOM by UHPLC–MS/MS. After oral application of DON and DON-3G, 84.8% ± 9.7% and 
40.3% ± 8.5% of the given dose were detected in the urine. In faeces, just trace amounts of 
metabolites were found. The data indicate that DON-3G is nearly completely hydrolysed in 
the gastro-intestinal tract of pigs, while the toxin seems to be rather stable after systemic 
absorption (Nagl et al. 2014a). 
Data regarding in vivo experiments on fumonisins in combination with fumonisin-esters are 
non-existent. A tabulated summary of key findings from these in vivo studies with modified 
mycotoxins are pointed out in Table 1. In Figure 1 a hypothetical graph is represented with 
indicating conditions resulting in the release of free mycotoxins from modified forms. 
 
Figure 1: graph with indicating conditions resulting in the release of free mycotoxins from (modified) forms 
















































































































Stomach no change 
11% DON (3-ADON 
13% DON (15-ADON) 
max. 19% ZEN no change no change no change 
Small intestine max. 5% DON-3G 
0% 3-ADON 
0% 15-ADON 
small amounts ZEN-14G no change no change no change 
Large intestine 
max. 2% DON-3G 
faeces: DON + DOM 
deacetylation + 
glucuronidation 
faeces: 40% ZEN 
faeces: 60% catabolites 
faeces: 40% ZEN 
faeces: 60% catabolites 
max. 99% fumonisins no change 
 
*
 based on in vitro and in vivo analysis; 
**
 based on in vitro analysis; deoxynivalenol=DON; deepoxy-deoxynivalenol=DOM; deoxynivalenol-3-glucoside=DON-3G; 3-and 
15-acetyl deoxynivalenol=3-ADON, 15-ADON; zearalenone-14-glucoside=ZEN-14G; zearalenone-14-sulphate=ZEN-14S 
 
CONCLUSION 
Scientific insights in toxicological fields have contributed greatly to the current knowledge of 
chemical hazards in food. Nevertheless, most concerns are related to the potential health 
effects of free mycotoxins and their modified forms. The metabolic fate of modified 
mycotoxin forms remains an unrevealed matter. Only a few reports focused on in vitro and in 
vivo metabolism studies of modified mycotoxins, and indicated the possible toxic relevance of 
these forms. The fraction of modified mycotoxin forms in food and feed is generally lower 
than their free forms. So, the toxic effects of contaminated food and feed in humans and 
animalia are caused by the free mycotoxins. However, based on the reported scientific results 
the sharp decreases of the modified forms in the small intestines suggest hydrolysis, as a 
consequence, the total exposure and risk assessment to mycotoxins might be underestimated. 
To confirm the statements made, repeated full-scale metabolism studies in relevant animal 
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